Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: Inhibition by riluzole

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 12, 2007, Pages 5671-5676

  Yoo, Min Heui ^a   Young, Hee Yoon ^a   Chung, Hyewon ^a   Kyung, Sook Cho ^a   Koh, Jae Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; MATRIX METALLOPROTEINASE; OXYGEN; RILUZOLE; SODIUM CHLORIDE; VASCULOTROPIN; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; DEXTRAN; DIAGNOSTIC AGENT; FLUORESCEIN DERIVATIVE; FLUORESCEIN DEXTRAN; FLUORESCEIN-DEXTRAN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

AMBIENT AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE EXACERBATION; DISEASE MODEL; DRUG ANTAGONISM; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; RAT; RETINA BLOOD VESSEL; RETINA HEMORRHAGE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; NEWBORN; RETROLENTAL FIBROPLASIA; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; DEXTRANS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID ANTAGONISTS; FLUORESCEIN ANGIOGRAPHY; FLUORESCEINS; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INJECTIONS, INTRAPERITONEAL; INSULIN; MATRIX METALLOPROTEINASES; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; RETINAL HEMORRHAGE; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; RILUZOLE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38549168468     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0395     Document Type: Article

References (34)

1. Kim BS, Chen J, Weinstein T, Noiri E, Goligorsk MS. VEGF expression in hypoxia and hyperglycemia: reciprocal effect on branching angiogenesis in epithelial-endothelial co-cultures. J Am Soc Nephrol. 2002;13:2027-2036.
2. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
3. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes. 1998;47:401-406.
4. Lorenzi M, Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus: call for data. Diabetes. 40;6:653-659.
5. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764-769.
6. Tanaka Y, Katoh S, Hori S, Miura M, Yamashita H. Vascular endothelial growth factor in diabetic retinopathy. Lancet. 1997;24:349: 1520.
7. Marsh S, Nakhoul FM, Skorecki K, et al. Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care. 2000;23:1375-1380.
8. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638-645.
9. Lu M, Amano S, Miyamoto K, et al. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci. 1999;40:3281-3286.
10. Ruberte J, Ayuso E, Navarro M, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest. 2004;113:1149-1157.
11. Paques M, Massin P, Gaudric A. Growth factors and diabetic retinopathy. Diabetes Metab. 1997;23:125-130.
12. Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest. 2003;111:1835-1842.
13. Doronzo G, Russo I, Mattiello L, Anfossi G, Bosia A, Trovati M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur J Clin Invest. 2004;34:664-673.
14. Yoo MH, Hyun HJ, Koh JY, Yoon YH. Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci. 2005;46:4780-4787.
15. Groeneveld GJ, Van Kan HJM, Kalmijn S, et al. Riluzole serum concentrations in patients with ALS. Neurology. 2003;61:1141-1143.
16. Borras-Blasco J, Plaza-Macias I, Navarro-Ruiz A, Peris-Marti J, Anton-Cano A. Riluzole as a treatment for amyotrophic lateral sclerosis. Rev Neurol. 1998;27:1021-1027.
17. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98: 2018-2026.
18. Gole GA, Gannon BJ, Goodger AM. Oxygen induced retinopathy: the kitten model re-examined. Aust J Ophthalmol. 1982;10:223-232.
19. Ventresca MR, Gonder JR, Tanswell AK. Oxygen-induced proliferative retinopathy in the newborn rat. Can J Ophthalmol. 1990;25: 186-189.
20. Ricci B. Oxygen-induced retinopathy in the rat model. Doc Ophthalmol. 1990;74:171-177.
21. Higgins RD, Yu K, Sanders RJ, Nandgaonkar BN, Rotschild T, Rifkin DB. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr Eye Res. 1999;18:20-27.
22. Beauchamp MH, Marrache AM, Hou X, et al. Platelet-activating factor in vasoobliteration of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002;43:3327-3337.
23. Phelps DL, Rosenbaum AL. Effects of marginal hypoxemia on recovery from oxygen-induced retinopathy in the kitten model. Pediatrics. 1984;73:1-6.
24. Phelps DL. Retinopathy of prematurity : an estimate of vision loss in the United States - 1979. Pediatrics. 1981;67:924-925.
25. Smith LE, Wesolowski E, McLellan A, et al Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
26. An international classification of retinopathy of prematurity. Pediatrics. 1984;74:127-133.
27. Ayala JE, Boustead JN, Chapman SC, et al. Insulin-mediated activation of activator protein-1 through the mitogen-activated protein kinase pathway stimulates collagenase-1 gene transcription in the MES 13 mesangial cell line. J Mol Endocrinol. 2004;33:263-280.
28. Keshet E. Preventing pathological regression of blood vessels. J Clin Invest. 2003;112:27-29.
29. Meininger V, Lacomblez L, Salachas F. What has changed with riluzole? J Neurol. 2000;247:VI19-VI22.
30. Doble A. Effects of riluzole in glutamatergic neurotransmission in the mammalian central nervous system, and other pharmacological effects. Rev Contemp Pharmacother. 1997;8:213-225.
31. Schiefer J, Landwehrmeyer GB, Lüesse HG, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Movement Disord. 2002; 17:748-757.
32. Ettaiche M, Fillacier K, Widmann C, Heurteaux C, Lazdunski M. Riluzole improves functional recovery after ischemia in the rat retina. Invest Ophthalmol Vis Sci. 1999;40:729-736.
33. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett. 1992;147:209-212.
34. Jehle T, Bauer J, Blauth E, et al. Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol. 2000;130:1227-1234.